To better assess the role of MARVELD1 in glioma, U87 cells, which presented a relative lower expression, were selected for overexpression assays, and U251 cells with a relative higher expression were chosen for knockdown assays. The gene discussed is MARVELD1; the disease is central nervous system cancer.